ABSTRACT
PURPOSE: To prospectively compare preoperative and postoperative measurements of intraocular pressure (IOP) using Goldmann applanation tonometry (GAT), noncontact tonometer (NCT), and Dynamic contour tonometer (DCT) in eyes undergoing myopic laser in situ keratomileusis (LASIK) and to examine the effects of preoperative corneal curvature and IOP, and the change in central corneal thickness (CCT). METHODS: One hundred six eyes of 53 patients underwent myopic LASIK with -5.3 +/- 2.3 (mean +/- SD) diopters. Within 4 weeks before and at 1 month after LASIK, IOP using GAT, NCT and DCT and CCT were measured. RESULTS: Postoperatively, although IOP was reduced in the three measurements, IOP changes in DCT (-0.9 +/- 1.7 mmHg) were significantly lower than in the GAT (-3.6 +/- 2.1 mmHg) and in the NCT (-4.7 +/- 1.9 mmHg) measurements (p < 0.001, Tukey test). In all the measurements, the decrease in the IOP increased with the higher preoperative IOP (p < 0.001). Changes in the CCT were significantly correlated in the GAT and NCT measurements (p < 0.015). CONCLUSIONS: IOP measurements using DCT minimized the changes in IOP readings after myopic LASIK in Japanese eye. This demonstrated that the DCT was effective for IOP monitoring after LASIK.
Subject(s)
Intraocular Pressure/physiology , Keratomileusis, Laser In Situ , Adolescent , Adult , Asian People , Female , Humans , Male , Middle Aged , Myopia/surgery , Prospective Studies , Tonometry, OcularABSTRACT
BACKGROUND: We report a case of a severe corneal disorder after lung cancer treatment with the epidermal growth factor receptor (EGFR) inhibitor, erlotinib hydrochloride (Tarceva). CASE: A 59-year-old man, who was referred to our cornea service, presented with blurred vision and pain OD. Visual acuity was 6/20. Slit-lamp examination showed a severe corneal epithelial defect and ocular inflammation OD. Eighteen months previously, he had been diagnosed with lung cancer and had been undergoing treatment with erlotinib for 6 months. He had no history of ocular surgery, trauma or diabetes. After topical antibiotic therapy was started and the erlotinib treatment was discontinued for 1 week, the corneal findings resolved completely. The visual acuity recovered to 20/20 after 8 weeks. CONCLUSION: An EGFR inhibitor used to treat lung cancer can cause severe corneal disorders including severe corneal defects and ocular inflammation. Clinicians should consider the possibility of erlotinib in cases of corneal disorders of uncertain etiology.
